AbolerIS Pharma Announces First Cohort Dosed in Phase 1 Study of ABO21009, a Novel Anti-CD45RC Antibody, for Rheumatoid Arthritis

-Company is advancing a new class of immunomodulators for autoimmune and inflammatory disorders with high unmet medical need- – ABO21009’s unique mechanism of action depletes pathogenic T and B cells, induces expansion of Tregs for lasting efficacy, and preserves overall immunity-…